Projects
Search from 1050 projects:
1050 Project(s)
MK-7902-005 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)
Mar 17, 2021The rationale for this study comes from preclinical models, in which lenvatinib decreased the tumor-associated macrophage (TAM) population, which is known as an immune-regulator in the tumor microenvironment. The decrease in TAM population was accomp...
Clinical Studies - Mar 17, 2021 - May 7, 2030
Scheduled
Project leader: Fischer Stefanie
A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Mar 15, 2021A Study to Evaluate Imetelstat (GRN163L) in Transfu-sion-Dependent Subjects with IPSS Low or Intermedi-ate-1 Risk Myelodysplastic Syndrome (MDS) that is Re-lapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment
Clinical Studies - Mar 15, 2021 - Apr 7, 2030
Scheduled
Project leader: Silzle Tobias
Members: Driessen Christoph, Fehr Martin, Hitz Felicitas, Lehmann Thomas
A phase 3, multicenter, open-label, randomized, study of
Mar 12, 2021Midostaurin plus chemotherapy is the standard therapy in AML for fit patients harboring a FLT3 mutation. However, on the molecular level, midostaurin is an unselective multikinaseinhibitor with rather weak inhibitory potential of mutated FLT3. Midost...
Clinical Studies - Mar 12, 2021 - Mar 19, 2030
Scheduled
Project leader: Schmid Sabine
A phase 3, multicenter, open-label, randomized, study of
Mar 12, 2021Midostaurin plus chemotherapy is the standard therapy in AML for fit patients harboring a FLT3 mutation. However, on the molecular level, midostaurin is an unselective multikinaseinhibitor with rather weak inhibitory potential of mutated FLT3. Midost...
Clinical Studies - Mar 12, 2021 - Mar 19, 2030
Scheduled
Project leader: Schmid Sabine
An open-label Phase 1/2a study of oral BAL101553
Mar 8, 2021Frühe Phase-II Studie zur Behandlung von IDH-Wildtyp Glioblastomen oder IDH-mutierten Astrozytomen WHO Grad IV nach Progression (jede Linie) mit Lisavanbulin als orale Monotherapie mit geringen Nebenwirkungen. Die Wirksamkeit der Behandlung mit Lisav...
Clinical Studies - Mar 8, 2021 - Feb 16, 2030
Scheduled
Project leader: Hundsberger Thomas
SAKK 17/18 Origin
Mar 5, 2021A significant number of patients with malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) are not cured with available treatments and will eventually relapse. After relapse treatment options are limited. Preclinical in vitro s...
Clinical Studies - Mar 5, 2021 - Dec 12, 2024
Scheduled
Project leader: Jörger Markus
Atezolizumab in combination with Bevacizumab and Chemotherapy versus Bevacizumab and Chemotherapy in recurrent ovarian cancer- a randomized Phase III trial An ENGOT Trial
Mar 4, 2021This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab and chemotherapy compared with placebo plus bevacizumab and chemotherapy in patients with recurrent ovarian-, fallopian tube, or primary peritoneal cancer with 1st or 2...
Clinical Studies - Mar 4, 2021 - Dec 24, 2025
Ongoing
Project leader: Hasler-Strub Ursula
CardioOnco - Diagnosing Preclinical Cardiac Dysfunction in Adult Childhood Cancer Survivors ‒ The CardioOnco study
Mar 1, 2021We aim to: 1. Assess preclinical cardiac dysfunction longitudinally using 2-dimensional (2D) and 3-dimensional (3D) conventional and 2D speckle tracking echocardiography. 2. Assess cardiopulmonary fitness using cardiopulmonary exercise testing. 3....
Clinical Studies - Mar 1, 2021 - Dec 31, 2030
Ongoing
Project leader: Scheler Eva
Members: Schneider Irene
Outcome von Patienten mit Kopf-Hals-Malignomen in der Hals-Nasen- Ohrenklinik am Kantonsspital St.Gallen
Mar 1, 2021Die Hals-Nasen-Ohren Klinik am Kantonsspital St.Gallen nimmt zusammen mit der Klinik für Radio-Onkologie und der Klinik für Medizinische Onkologie/Hämatologie eine Zentrumsfunktion in der Ostschweiz für die Behandlung von Kopf-Hals-Tumorpatienten ein...
Clinical Studies - Mar 1, 2021 - Mar 9, 2022
Automatically Closed
An open-label Phase 1/2a study of oral BAL101553
Feb 16, 2021Frühe Phase-II Studie zur Behandlung von IDH-Wildtyp Glioblastomen oder IDH-mutierten Astrozytomen WHO Grad IV nach Progression (jede Linie) mit Lisavanbulin als orale Monotherapie mit geringen Nebenwirkungen. Die Wirksamkeit der Behandlung mit Lisav...
Clinical Studies - Feb 16, 2021 - Mar 8, 2030
Scheduled
A PHASE II, OPEN-LABEL, MULTICENTER STUDY
Feb 12, 2021Die Studie dient zur Beurteilung der Wirkung, der Gabe von Tecentriq (Atezolizumab) und Tiragolumab mit oder ohne Chemotherapie bei Patienten, deren Lungenkrebs operiert werden kann. Es soll herausgefunden werden, ob und/oder wie lange diese Arzneim...
Clinical Studies - Feb 12, 2021 - Mar 8, 2030
Scheduled
Project leader: Fischer Stefanie
Members: Früh Martin, Jörger Markus, Bickel Angelika, Appenzeller Christina
EINE OFFENE, MULTIZENTRISCHE PHASE-II-STUDIE ZUR BEURTEILUNG DER SICHERHEIT UND WIRKSAMKEIT DER NEOADJUVANTEN UND ADJUVANTEN THERAPIE VON TIRAGOLUMAB PLUS ATEZOLOZUMAB MIT ODER OHNE PLATINBASIERTER CHEMOTHERAPIE BEI PATIENTEN MIT NICHT VORBEHANDELTEM LOKAL FORTGESCHRITTENEM OPERABLEM NICHT KLEINZELLIGEM LUNGENKREBS IM STADIUM II, IIIA ODER EINER BESTIMMTEN FORM IM STADIUM IIIB
Feb 12, 2021Das Ziel dieser Studie ist es die Wirkungen, ob positiv oder negativ, von Tecentriq (Atezolizumab) und Tiragolumab mit oder ohne Chemotherapie bei Patienten, deren Lungenkrebs operiert werden kann, zu beurteilen. Es soll herausgefunden werden, ob und...
Clinical Studies - Feb 12, 2021 - Dec 31, 2026
Ongoing
Project leader: Fischer Stefanie
Role of Brachytherapy in the post-operative management of endometrial cancer: decision-making analysis among European experts“
Feb 4, 2021To better understand decision-making processes for postoperative brachytherapy in endometrial cancer we want to initiate a project using an approach developed in our institution (objective consensus methodology) among European experts for this indica...
Clinical Studies - Feb 4, 2021 - Oct 31, 2021
Automatically Closed
Project leader: Glatzer Markus
HIT-Studie
Feb 1, 2021Targeted correction of plasma sodium levels in hospitalized patients with hyponatremia: a randomized, controlled, parallel-group trial with blinded outcome assessment
Clinical Studies - Feb 1, 2021 - Dec 31, 2025
Ongoing
Project leader: Bilz Stefan
Members: Bontognali Martina, Räss Andrea, Rothlin Silvia, Grillmayr Victoria
I6T-MC-AMBI
Feb 1, 2021A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in participants with Moderately to Severely Active Ulcerative Colitis
Clinical Studies - Feb 1, 2021 - Jan 1, 2024
Completed
Project leader: Brand Stephan
Members: Smolders Jolijn, Krieger-Grübel Claudia
Development of the European Organisation for Research and Treatment of Cancer (EORTC)/ Cutaneous Lymphoma Task Force (CLTF) questionnaire to assess HRQoL in cutaneous lymphoma
Feb 1, 2021
Clinical Studies - Feb 1, 2021 - Aug 25, 2023
Ongoing
Project leader: Cozzio Antonio
RECOVER: Rheumatoid Covid-19 Vaccine Immune Response
Feb 1, 2021Untersuchung der Sicherheit und Effektivität von mRNA basierten COVID-19 Impfungen bei Patienten mit rheumatoider Arthritis - ein exploratives Forschungsprojekt
Clinical Studies - Feb 1, 2021 - Dec 31, 2022
Completed
Project leader: Rubbert-Roth Andrea
Members: Schmiedeberg Kristin, Bartz-Batliner Mira, Peischl Riana, Peischl Shirin, Sasselli Clelia, Hutz Carina Liane
I6T-MC-AMAP
Jan 29, 2021A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Ulcerative Colitis LUCENT 3
Clinical Studies - Jan 29, 2021 - Dec 1, 2024
Ongoing
Project leader: Brand Stephan
Members: Krieger-Grübel Claudia, Smolders Jolijn
VitCov Studie
Jan 25, 2021High Dose Vitamin-D-substitution in Patients with COVID-19: a randomized, double blind, placebo controlled, multi-centre Study. The objective of the study is to test the hypothesis that patients with vitamin D deficiency suffering from COVID-19 trea...
Clinical Studies - Jan 25, 2021 - Dec 31, 2021
Automatically Closed
Project leader: Brändle Michael
Members: Bloch Nando, Räss Andrea
ESSENCE
Jan 1, 2021
Clinical Studies - Jan 1, 2021 - Dec 31, 2026
Ongoing
Project leader: Bilz Stefan